外科理论与实践

外科理论与实践 >

2024 , Vol. 29 >Issue 03: 264 - 269

DOI: https://doi.org/10.16139/j.1007-9610.2024.03.14

综述

结肠直肠癌肿瘤疫苗研究现状及展望

  • 贾文清 综述 ,
  • 张弢 ,
  • 赵任 审校
展开
  • 上海交通大学医学院附属瑞金医院普外科 上海市消化外科研究所，上海 200025
赵任，E-mail: zhaorensurgeon@aliyun.com

收稿日期: 2024-06-11

  网络出版日期: 2024-09-03

基金资助

国家自然科学基金(82202839);上海申康中心促进市级医院临床技能与临床创新三年行动计划(SHDC2020CR1026B)

收起

Research status and prospects of colorectal cancer vaccine

  • JIA Wenqing ,
  • ZHANG Tao ,
  • ZHAO Ren
Expand
  • Department of General Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2024-06-11

  Online published: 2024-09-03

Fold

摘要

结肠直肠癌（CRC）是全球发病率排名第3、但死亡率排名第2的恶性肿瘤。肿瘤疫苗是一种新型免疫治疗方式，向机体递呈肿瘤抗原，诱导抗肿瘤免疫应答，以形成长期免疫记忆。本文综述不同类型CRC疫苗近5年代表性临床/基础研究进展并展望未来。

关键词： 肿瘤疫苗; 结肠直肠癌; 新生抗原; 纳米疫苗

本文引用格式

贾文清 综述 , 张弢 , 赵任 审校 . 结肠直肠癌肿瘤疫苗研究现状及展望[J]. 外科理论与实践, 2024 , 29(03) : 264 -269 . DOI: 10.16139/j.1007-9610.2024.03.14

Abstract

Colorectal cancer(CRC) ranks in third place in terms of incidence but second in terms of mortality. Cancer vaccine, as a novel immunotherapy, presents tumor antigens to human immune system and further elicits anti-tumor immune response, leading to long-term immune memory. This review summarized representative research progress in both clinical and basic scenario of past five years, and prospected the future of CRC vaccine.

Key words： Cancer vaccine; Colorectal cancer(CRC); Neoantigen; Nanovaccine

参考文献

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2] ANDRé T, SHIU K K, KIM T W, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23):2207-2218.
[3] LENZ H J, VAN CUTSEM E, LUISA LIMON M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase Ⅱ checkmate 142 study[J]. J Clin Oncol, 2022, 40(2):161-170.
[4] CARLSEN L, HUNTINGTON K E, EL-DEIRY W S. Immunotherapy for colorectal cancer: mechanisms and predictive biomarkers[J]. Cancers(Basel), 2022, 14(4):1028.
[5] SAXENA M, VAN DER BURG S H, MELIEF C J M, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6):360-378.
[6] SAHIN U, TüRECI ?. Personalized vaccines for cancer immunotherapy[J]. Science, 2018, 359(6382):1355-1360.
[7] JIA W, ZHANG T, HUANG H, et al. Colorectal cancer vaccines: the current scenario and future prospects[J]. Front Immunol, 2022, 13:942235.
[8] HUBBARD J M, T?KE E R, MORETTO R, et al. Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase Ⅰb study[J]. Clin Cancer Res, 2022, 28(13):2818-2829.
[9] PASCOLUTTI R, YETURU L, PHILIPPIN G, et al. ATP128 clinical therapeutic cancer vaccine activates NF-κB and IRF3 pathways through TLR4 and TLR2 in human monocytes and dendritic cells[J]. Cancers(Basel), 2022, 14(20):5134.
[10] KOPETZ S, PRENEN H, SHARMA S, et al. SO-11 KISIMA-01 trial: safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage Ⅳ colorectal cancer - preliminary results from a phase Ⅰb study[J]. Ann Oncol, 2021, 32:S206-S207.
[11] ZHENG Y, FU Y, WANG P P, et al. Neoantigen: a pro-mising target for the immunotherapy of colorectal cancer[J]. Dis Markers, 2022, 2022:8270305.
[12] SAHIN U, DERHOVANESSIAN E, MILLER M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature, 2017, 547(7662):222-226.
[13] YU Y J, SHAN N, LI L Y, et al. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer[J]. Cancer Immunol Immunother, 2023, 72(7):2045-2056.
[14] PANT S, WAINBERG Z A, WEEKES C D, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial[J]. Nat Med, 2024, 30(2):531-542.
[15] LIU C, SHI Q, HUANG X, et al. mRNA-based cancer therapeutics[J]. Nat Rev Cancer, 2023, 23(8):526-543.
[16] LOPEZ J S, CAMIDGE R, IAFOLLA M, et al. Abstract CT301: a phase Ⅰb study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors[J]. Cancer Res, 2020, 80(16_Supplement):CT301-CT301.
[17] PALMER C D, RAPPAPORT A R, DAVIS M J, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results[J]. Nat Med, 2022, 28(8):1619-1629.
[18] CATENACCI D V, LIAO C Y, MARON S, et al. 960MO Clinical outcomes and immune responses in a phase Ⅰ/Ⅱ study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC[J]. Ann Oncol, 2021, 32:S830-S831.
[19] GRISTONE BIOLOGY. Gritstone announces updated overall survival results from granite phase Ⅰ/Ⅱ study and poster at SITC 2022[EB/OL]. (2022-11-10)[2024-06-11]. https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-announces-updated-overall-survival-results-granite.
[20] REN Y, MANOHARAN T, LIU B, et al. Circular RNA as a source of neoantigens for cancer vaccines[J]. J Immunother Cancer, 2024, 12(3):e008402.
[21] SMALL E J, SCHELLHAMMER P F, HIGANO C S, et al. Placebo-controlled phase Ⅲ trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer[J]. J Clin Oncol, 2006, 24(19):3089-3094.
[22] RODRIGUEZ J, CASTA?óN E, PEREZ-GRACIA J L, et al. A randomized phase Ⅱ clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis[J]. J Immunother Cancer, 2018, 6(1):96.
[23] ESPA?OL-REGO M, FERNáNDEZ-MARTOS C, ELEZ E, et al. A phase Ⅰ-Ⅱ multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study[J]. Cancer Immunol Immunother, 2023, 72(4):827-840.
[24] MARUOKA S, OJIMA T, IWAMOTO H, et al. Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro[J]. Sci Rep, 2022, 12(1):3295.
[25] HARRIS J E, RYAN L, HOOVER H C, et al. Adjuvant active specific immunotherapy for stage Ⅱ and Ⅲ colon cancer with an autologous tumor cell vaccine: eastern cooperative oncology group study E5283[J]. J Clin Oncol, 2000, 18(1):148-157.
[26] BAARS A, CLAESSEN A M E, WAGSTAFF J, et al. A phase Ⅱ study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage Ⅲ colon carcinoma[J]. Br J Cancer, 2002, 86(8):1230-1234.
[27] YARCHOAN M, HUANG C Y, ZHU Q, et al. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer[J]. Cancer Med, 2020, 9(4):1485-1494.
[28] JIA W, SHEN X, GUO Z, et al. The future of cancer vaccines against colorectal cancer[J]. Expert Opin Biol Ther, 2024, 24(4):269-284.
[29] LAROCCA C, SCHLOM J. Viral vector-based therapeutic cancer vaccines[J]. Cancer J, 2011, 17(5):359-371.
[30] MORSE M A, CHAUDHRY A, GABITZSCH E S, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients[J]. Cancer Immunol Immunother, 2013, 62(8):1293-1301.
[31] REDMAN J M, TSAI Y T, WEINBERG B A, et al. A randomized phase Ⅱ trial of mFOLFOX6 + Bevacizumab alone or with AdCEA vaccine + Avelumab immunotherapy for untreated metastatic colorectal cancer[J]. Oncologist, 2022, 27(3):198-209.
[32] OLADEJO M, PATERSON Y, WOOD L M. Clinical experience and recent advances in the development of Listeria-based tumor immunotherapies[J]. Front Immunol, 2021, 12:642316.
[33] YU Y, ZHANG J, NI L, et al. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer[J]. Hum Vaccin Immunother, 2022, 18(1):1-11.
[34] CLEYLE J, HARDY M P, MINATI R, et al. Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability[J]. Mol Cell Proteomics, 2022, 21(5):100228.
[35] PLEGUEZUELOS-MANZANO C, PUSCHHOF J, ROSENDAHL HUBER A, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli[J]. Nature, 2020, 580(7802):269-273.
[36] DEJEA C M, FATHI P, CRAIG J M, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria[J]. Science, 2018, 359(6375):592-597.
[37] HOLT R A. Oncomicrobial vaccines: the potential for a Fusobacterium nucleatum vaccine to improve colorectal cancer outcomes[J]. Cell Host Microbe, 2023, 31(1):141-145.
[38] PADMA S, PATRA R, SEN GUPTA P S, et al. Cell surface fibroblast activation protein-2 (fap2) of Fusobacterium nucleatum as a vaccine candidate for therapeutic intervention of human colorectal cancer: an immunoinformatics approach[J]. Vaccines(Basel), 2023, 11(3):525.
[39] PRIYAMVADA P, RAMAIAH S. Pan-genome and reverse vaccinology approaches to design multi-epitope vaccine against Epstein-Barr virus associated with colorectal cancer[J]. Immunol Res, 2023, 71(6):887-908.
[40] KHAN S, AZIZ S, WAQAS M, et al. Targeted vaccine development against bilophila wadsworthia to curb colon diseases: a multiepitope approach based on reverse vaccinology and computational analysis[J]. Int J Biol Macromol, 2023, 250:126002.
[41] MITCHELL M J, BILLINGSLEY M M, HALEY R M, et al. Engineering precision nanoparticles for drug deli-very[J]. Nat Rev Drug Discov, 2021, 20(2):101-124.
[42] BLOOM K, VAN DEN BERG F, ARBUTHNOT P. Self-amplifying RNA vaccines for infectious diseases[J]. Gene Ther, 2021, 28(3-4):117-129.
[43] SCHIMANSKI C C, KASPER S, HEGEWISCH-BECKER S, et al. Adjuvant MUC vaccination with te-cemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase Ⅱ trial (LICC)[J]. Oncoimmunology, 2020, 9(1):1806680.
[44] MOEHLER M, FOLPRECHT G, HEINEMANN V, et al. Survival after secondary liver resection in metastatic colorectal cancer: comparing data of three prospective randomized European trials ( LICC, CELIM, FIRE ‐3)[J]. Int J Cancer, 2022, 150(8):1341-1349.
[45] HORNBUCKLE K, FRITZ C D L. What is lynch syndrome?[J]. JAMA, 2024, 332(2):178.
[46] BOLIVAR A M, DUZAGAC F, SINHA K M, et al. Advances in vaccine development for cancer prevention and treatment in lynch syndrome[J]. Mol Aspects Med, 2023, 93:101204.
[47] D’ALISE M, WILLIS J, LEONI G, et al. 1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy lynch syndrome carriers: interim results from phase Ⅰ cancer interception trial[J]. BMJ Publishing Group Ltd,2023,A1751-A1751.
[48] JACKSON K, SAMADDAR S, MARKIEWICZ M A, et al. Vaccination-based immunoprevention of colorectal tumors: a primer for the clinician[J]. J Clin Gastroenterol, 2023, 57(3):246-252.
Options
文章导航

/

〈 〉